Content about Amidines

October 19, 2010
FDA approves BI's Pradaxa

The Food and Drug Administration approved a drug for preventing strokes and blood clots in...

SILVER SPRING, Md. The Food and Drug Administration approved a drug for preventing strokes and blood clots in patients with abnormal heart rhythm, the agency said Tuesday.

 

The FDA announced the approval of Pradaxa (dabigatran etexilate) capsules, an anticlotting drug made by Boehringer Ingelheim for patients with atrial fibrillation, a type of abnormal heart rhythm that affects more than 2 million Americans.

 

 

September 20, 2010
FDA advisory committee recommends approval of BI's atrial fibrillation drug

A Food and Drug Administration advisory committee has recommended approval of a drug for patients...

RIDGEFIELD, Conn. A Food and Drug Administration advisory committee has recommended approval of a drug for patients with atrial fibrillation.

 

The FDA cardiovascular and renal drugs advisory committee voted unanimously to recommend approval for Boehringer Ingelheim's Pradaxa (dabigatran etexilate), for preventing strokes in atrial fibrillation patients. For the last 50 years, warfarin has been the only oral anticoagulant drug available for this purpose.

 

 

July 6, 2010
Decision Resources: Atrial fibrillation treatments will expand market size to $7 billion

Launch and use of new heart drugs will drive the market for drugs to treat...